• 單元主視覺

November 2018 Sunny’s ANDA of Aminocaproic Acid Tablets has been approved by US FDA

November 2018 Sunny’s ANDA of Aminocaproic Acid Tablets has been approved by US FDA
2018/11/28
Sunny Pharmtech Inc. announced that its ANDA(“Abbreviated New Drug Application”) of Aminocaproic Acid Tablets has been officially approved by US FDA on 2018/11/28.  Aminocaproic Acid Tablets are indicated for the treatment of acute bleeding syndromes due to elevated fibrinolytic activity.  Except for the Brand drug, Sunny is the first generic company of Aminocaproic Acid Tablets in the US market.  
 
According to IMS data, the total sales of Aminocaproic Acid Tablets in the US were approximately US $25 million for the 12 months ended December 2017.  Sunny is now preparing for launch accordingly and will commercialize the product through Sunny’s business partner in the US market. 
Home/News/News/November 2018 Sunny’s ANDA of Aminocaproic Acid Tablets has been approved by US FDA